Corneal Cross-Linking for Pediatric Keratoconus

Bogumiła Wójcik-Niklewska1,2, Erita Filipek1,2, Paweł Janik3

  • 1Department of Pediatric Ophthalmology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-055 Katowice, Poland.

PubMed

Insights

Corneal cross-linking (CXL) effectively halts keratoconus progression in pediatric patients. Long-term ophthalmic monitoring is recommended for those under 18 post-procedure.

Area of Science:

  • Ophthalmology
  • Corneal Surgery
  • Pediatric Eye Care

Background:

  • Keratoconus is a progressive corneal ectasia affecting young individuals.
  • Early intervention is crucial to prevent vision loss.
  • Corneal cross-linking (CXL) is a standard treatment for keratoconus.

Purpose of the Study:

  • To evaluate the efficacy of corneal cross-linking (CXL) in pediatric patients with keratoconus.
  • To assess changes in visual acuity, intraocular pressure, keratometry, and pachymetry after CXL.
  • To determine if CXL can halt or slow keratoconus progression in children.

Main Methods:

  • 111 eyes of 74 pediatric patients (mean age 15 years) with keratoconus underwent CXL.
  • The Amsler-Krumeich system was used for keratometric qualification.
  • Corneal collagen cross-linking involved ultraviolet light and riboflavin drops.
  • Parameters analyzed included visual acuity, intraocular pressure, keratometry, and pachymetry pre- and post-procedure.

Main Results:

  • No statistically significant changes were observed in visual acuity, intraocular pressure, or astigmatism post-CXL.
  • Mean keratometry showed a slight, non-significant decrease after CXL.
  • A statistically significant reduction in mean corneal thickness (pachymetry) was noted post-CXL.

Conclusions:

  • Corneal cross-linking (CXL) is an effective treatment for preventing keratoconus progression in pediatric patients.
  • While CXL appears safe and effective, continued ophthalmic follow-up is essential for pediatric patients.
  • Further detailed follow-up is highly advisable for individuals under 18 who have undergone CXL.
Abstract